Thickened inner hypoechoic layer of the gallbladder wall in the diagnosis of anomalous pancreaticobiliary ductal union with endosonography

Tanno, Satoshi; Obara, Takao; Maguchi, Hiroyuki; Mizukami, Yusuke; Shudo, Ryushi; Fujii, Tsuneshi; Takahashi, Kuniyuki; Nishino, Noriyuki; Arisato, Satoshi; Saitoh, Yusuke; Ura, Hideki; Kohgo, Yutaka

doi:10.1016/s0016-5107(97)70007-5

Cited by 14 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the pancreatic and bile ducts, the muscularis propria of the duodenum and pancreatic parenchyma can be examined by EUS, confirming that the pancreaticobiliary junction lies outside the duodenal wall, irrespective of the length of the common channel. Furthermore, the bile duct and gallbladder can be studied in detail in a series of scans following the diagnosis of PBM [57].…”

Section: Commentsmentioning

confidence: 99%

Japanese clinical practice guidelines for pancreaticobiliary maljunction

et al. 2012

View full text Add to dashboard Cite

There have been no clinical guidelines for the management of pancreaticobiliary maljunction (PBM). The Japanese Study Group on Pancreaticobiliary Maljunction (JSPBM) has proposed to establish clinical practice guidelines on how to deal with PBM, with the support of the Japan Biliary Association (JBA). Because the body of evidence-based literature is relatively small, we decided to create guidelines based on the consensus of experts, using the medical literature for reference. A total of 46 clinical questions (CQs) were considered by the members of the editorial committee responsible for the guidelines. The CQs covered distinct aspects of PBM: (1) Concepts and Pathophysiology (10 CQs); (2) Diagnosis (10 CQs); (3) Pancreatobiliary complications (9 CQs); and (4) Treatments and prognosis (17 CQs). Statements and comments for each CQ were prepared by the guidelines committee members and collaborating partners. The CQs were completed after review by members of the editorial committee, meetings of this committee, public comments on the homepages of the JSPBM and the JBA, public hearings, and assessment and approval by the guidelines evaluation board. PBM includes cases where the bile duct is dilated (PBM with biliary dilatation) and those in which it is not (PBM without biliary dilatation). In these guidelines, PBM with biliary dilatation is defined as being identical to congenital biliary dilatation of Todani type I (except for type Ib) and type IV-A, both of which are accompanied by PBM in almost all cases. These guidelines are created to provide assistance in the clinical practice of PBM management; their contents focus on clinical utility, and they include general information on PBM to make this disease more widely recognized.

show abstract

Section: Commentsmentioning

confidence: 99%

Japanese clinical practice guidelines for pancreaticobiliary maljunction

et al. 2012

View full text Add to dashboard Cite

show abstract

“…A frequent association of biliary tract carcinoma and APBDU is well recognized [12][13][14][15][16][17][18][19] , especially in the undilated type APBDU [20,21] . Mori [7] had reported that among 698 patients subjected to endoscopic retrograde cholangiopancreatography, APBDU was found in 6 patients (0.9 %).…”

Section: Discussionmentioning

confidence: 99%

“…The clinicopathological data showed that the thickness of the gallbladder wall was visualized in 26/28 (92.9 %) patients. Some researchers [20][21][22] had reported that patients with adenomyomatosis (a presumed premalignant lesion of the gallbladder) were frequently associated with the undilated type APBDU. Tanno [23] reported 15/24 (63 %) of APBDU patients had epithelial hyperplasia of the gallbladder, the incidence of which was significantly higher in the gallbladders of undilated type APBDU patients (91 %) than that in dilated type patients (38 %).…”

Section: Discussionmentioning

confidence: 99%

Bile from a patient with anomalous pancreaticobiliary ductal union promotes the proliferation of human cholangiocarcinoma cellsviaCOX-2 pathway

Zou²,

Liu³

et al. 2003

WJG

View full text Add to dashboard Cite

AIM:To explore the effects of COX-2 gene in the proliferative activity induced by bile from anomalous pancreaticobiliary ductal union (APBDU) on human cholangiocarcinoma cell line. METHODS:Bile sample from APBDU and normal bile sample were used for this study. The proliferative effect of bile was measured by methabenzthiazuron (MTT) assay; COX-2 mRNA was examined by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR). Cell cycle was analyzed by flow cytometry (FCM), and the PGE 2 levels in the supernatant of cultured cholangiocarcinoma cells were quantitated by enzyme-linked immunoabsordent assay (ELISA). RESULTS:Bile from APBDU can significantly promote the proliferation of human cholangiocarcinoma QBC939 cells compared with normal bile (P=0.005) and upregulated remarkably their COX-2 mRNA expression (P=0.004). The proliferative activity of APBDU bile can be abolished by addition of cyclooxygenase-2 specific inhibitor celecoxib. CONCLUSION:Bile from APBDU can promote the proliferation of human cholangiocarcinoma QBC939 cells via COX-2 pathway.Wu GS, Zou SQ, Liu ZR, Wang DY. Bile from a patient with anomalous pancreaticobiliary ductal union promotes the proliferation of human cholangiocarcinoma cells via COX-2 pathway.

show abstract

“…218 It has been confirmed pathologically in as many as 91% of patients when biliary ducts are not dilated. 219 Finally, the diffuse papillomatosis of the biliary tract may also involve the gallbladder and may manifest as a thickening with a protruding mass 220 combined with biliary duct polyps.…”

Section: Other Etiologies Of Wall Thickeningmentioning

confidence: 99%